Aktas, O., Hartung, H., Smith, M. A., Rees, W. A., Fujihara, K., Paul, F., . . . Cree, B. A. (2023). Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: Analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery & Psychiatry, 94(9), 757-768. https://doi.org/10.1136/jnnp-2022-330412
Citace podle Chicago (17th ed.)Aktas, Orhan, et al. "Serum Neurofilament Light Chain Levels at Attack Predict Post-attack Disability Worsening and Are Mitigated by Inebilizumab: Analysis of Four Potential Biomarkers in Neuromyelitis Optica Spectrum Disorder." Journal of Neurology, Neurosurgery & Psychiatry 94, no. 9 (2023): 757-768. https://doi.org/10.1136/jnnp-2022-330412.
Citace podle MLA (9th ed.)Aktas, Orhan, et al. "Serum Neurofilament Light Chain Levels at Attack Predict Post-attack Disability Worsening and Are Mitigated by Inebilizumab: Analysis of Four Potential Biomarkers in Neuromyelitis Optica Spectrum Disorder." Journal of Neurology, Neurosurgery & Psychiatry, vol. 94, no. 9, 2023, pp. 757-768, https://doi.org/10.1136/jnnp-2022-330412.